I Would Rebuild My Portfolio With Just These 3 Stocks If I Lost Everything Tomorrow

I support buying NVIDIA, Eli Lilly, and Johnson & Johnson, and if a occurrence took my brokerage connection to zero tomorrow, those are the 3 tickers I would commencement typing successful again connected time one. They each bash thing I cannot replicate by being clever.

Why the bargain fastener stays progressive connected NVIDIA

NVIDIA (NASDAQ:NVDA) is the 1 presumption wherever I person stopped pretending I tin clip it. Q1 FY27 gross came successful astatine $81.61 billion, up 85.23% twelvemonth implicit year, with non-GAAP EPS of $1.87 against a $1.7738 estimate. Free currency travel unsocial was $48.55 cardinal successful a azygous quarter. Full twelvemonth FY26 escaped currency travel reached $96.58 billion. That is the currency instrumentality I americium buying.

The superior instrumentality displacement sealed it for me. The quarterly dividend went from $0.01 to $0.25, a caller $80 cardinal buyback authorization landed connected apical of $38.5 cardinal remaining, and astir $20 cardinal came backmost to shareholders successful Q1.

Jensen Huang framed the rhythm plainly: "The buildout of AI factories, the largest infrastructure enlargement successful quality history, is accelerating astatine bonzer speed." Supply commitments of $119 cardinal archer maine absorption sees the request the aforesaid mode I do.

The honorable hazard is China. The Q2 usher assumes zero Data Center compute gross from China, and nary H20 shipped past quarter. I respect it. I besides enactment that the institution is guiding $91 cardinal for Q2 anyway. The shares are up 12.01% twelvemonth to day and 47.42% implicit 1 year, and the net powerfulness is increasing faster than the multiple.

Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and Johnson & Johnson didn't marque the cut. Grab the names FREE today.

Eli Lilly is the franchise I support underestimating

Eli Lilly (NYSE:LLY) keeps proving maine excessively cautious. Q1 2026 gross was $19.80 billion, up 55.5% YoY, with EPS of $8.55 against a $6.79 estimate. Mounjaro unsocial delivered $8.66 cardinal (125% YoY growth) and Zepbound added $4.16 cardinal (80% YoY). Full twelvemonth guidance was raised to $82 to $85 cardinal successful gross and $35.5 to $37 successful non-GAAP EPS.

Foundayo, the archetypal oral GLP-1 that tin beryllium taken immoderate clip of time without nutrient oregon h2o restrictions, is the catalyst I support coming backmost to. CEO David Ricks said "Foundayo volition meaningfully grow the fig of radical who tin payment from GLP-1s."